Related Experiment Videos
Linkage of elevated ets-2 expression to hepatocarcinogenesis
Yasuhiro Ito1, Eiji Miyoshi, Tsutomu Takeda
1Department of Surgery, Kuma Hospital, Kobe, Japan. ito01@kuma-h.or.jp
Anticancer Research
|August 15, 2002
Summary
The transcription factor ets-2 is linked to liver cancer progression. Lower ets-2 expression in hepatocellular carcinoma (HCC) correlates with advanced disease and poorer survival, suggesting a role in malignant transformation.
Area of Science:
- Oncology
- Molecular Biology
- Hepatology
Background:
- Ets-2, a transcription factor, has been previously associated with carcinoma progression.
- Its role in hepatocellular carcinoma (HCC) and liver malignant transformation requires further investigation.
Purpose of the Study:
- To investigate the expression and clinical significance of ets-2 in HCC.
- To assess the role of ets-2 in the malignant transformation of the liver.
Main Methods:
- Immunohistochemical analysis of ets-2 expression.
- Study cohort included 91 HCC, 46 noncancerous lesions, 8 atypical adenomatous hyperplasias, and 14 normal liver controls.
Main Results:
- Ets-2 expression was significantly lower in HCC compared to noncancerous lesions and atypical adenomatous hyperplasias.
- Lower ets-2 levels in HCC correlated with advanced stage, larger tumor size, high proliferation, poor differentiation, portal invasion, intrahepatic metastasis, and shorter disease-free survival.
- Ets-2 labeling index was significantly lower in normal liver tissue than in noncancerous lesions.
Conclusions:
- Ets-2 expression is significantly altered during hepatocellular carcinoma development.
- These findings highlight ets-2's predominant role in liver malignant transformation and its potential as a prognostic marker in HCC.